TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. (Q34188474)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. |
scientific article |
Statements
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients (English)
Jacob Nattermann
Ulrich Spengler
Andreas Glässner
Tilman Sauerbruch
Marianne Eisenhardt
Katarina Riesner
Franziska Wolter
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference